Association between adverse effects under azathioprine therapy and inosine triphosphate pyrophosphatase activity in patients with chronic inflammatory bowel disease

Therapeutic Drug Monitoring

Volumn 33, Issue 3, 2011, Pages 321-328

  Shipkova, Maria ^a   Franz, Jutta ^a   Abe, Manabu ^a   Klett, Corinne ^a   Wieland, Eberhard ^a   Andus, Tilo ^a  

^a KLINIKUM STUTTGART   (Germany)

Author keywords

Chronic inflammatory bowel disease; Drug toxicity; Genotype; Inosine triphosphate pyrophosphatase; Phenotype; Therapeutic drug monitoring

Indexed keywords

AZATHIOPRINE; INORGANIC PYROPHOSPHATASE; INOSINE TRIPHOSPHATE; INOSINE TRIPHOSPHATE PYROPHOSPHATASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COMORBIDITY; ENTERITIS; ENZYME ACTIVITY; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PHENOTYPE; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; AZATHIOPRINE; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; POLYMORPHISM, GENETIC; PYROPHOSPHATASES; YOUNG ADULT;

EID: 80051788056     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31821a7c34     Document Type: Article

References (37)

1. Karas-Kuzelicki N, Mlinaric-Rascan I. Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond. Pharmacogenomics. 2009;10:1309-1322.
2. Fotoohi AK, Coulthard SA, Albertioni F. Thiopurines: factors influencing toxicity and response. Biochem Pharmacol. 2010;79:1211-1220.
3. Schütz E, Gummert J, Armstrong VW, et al. Azathoprine pharmacogenetics: the relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation. Eur J Clin Chem Biochem. 1996;34:199-205. (Pubitemid 26107631)
4. Dong XW, Zheng Q, Zhu MM, et al. Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease. World J Gastroenterol. 2010;16:3187-3195.
5. Van Asseldonk DP, de Boer NK, Peters GJ, et al. On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance. Curr Drug Metab. 2009;10:981-997.
6. Derijks LJ, Wong DR. Pharmacogenetics of thiopurines in inflammatory bowel disease. Curr Pharm Des. 2010;16:145-154.
7. Higgs JE, Payne K, Roberts C, et al. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics. 2010;11:177-188.
8. Marsh S, Van Booven DJ. The increasing complexity of mercaptopurine pharmacogenomics. Clin Pharmacol Ther. 2009;85:139-141.
9. Lin S,McLennan AG, Ying K, et al. Cloning, expression, and characterization of a human inosine triphosphate pyrophosphatase encoded by the ITPA gene. J Biol Chem. 2001;276:18695-18701.
10. Sumi S, Marinaki AM, Arenas M, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. J Hum Genet. 2002;111: 360-367. (Pubitemid 36075062)
11. Maeda T, Sumi S, Ueta A, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. Mol Genet Metab. 2005;85:271-279. (Pubitemid 41074110)
12. Atanasova S, Shipkova M, Svinarov D, et al. Analysis of ITPA phenotypegenotype correlation in the Bulgarian population revealed a novel gene variant in exon 6. Ther Drug Monit. 2007;29:6-10. (Pubitemid 46279870)
13. Shipkova M, Lorenz K, Oellerich M, et al. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin Chem. 2006;52:240-247. (Pubitemid 43185485)
14. Kudo M, Saito Y, Sasaki T, et al. Genetic variations in the HGPRT, ITPA, IMPDH1, IMPDH2, and GMPS genes in Japanese individuals. Drug Metab Pharmacokinet. 2009;24:557-564.
15. Marsh S, King CR, Ahluwalia R, et al. Distribution of ITPA P32T alleles in multiple world populations. J Hum Genet. 2004;49:579-581. (Pubitemid 39506541)
16. Marinaki AM, Ansari A, Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics. 2004;14:181-187. (Pubitemid 38373112)
17. Xiong H, Xin HW, Wu XC, et al. Association between inosine triphosphate pyrophosphohydrolase deficiency and azathioprine-related adverse drug reactions in the Chinese kidney transplant recipients. Fundam Clin Pharmacol. 2010;24:393-400.
18. Ansari A, Arenas M, Greenfield SM, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:973-983.
19. Uchiyama K, Nakamura M, Kubota T, et al. Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment. J Gastroenterol. 2009;44:197-203.
20. Zelinkova Z, Derijks LJ, Stokkers PC, et al. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol. 2006;4:44-49. (Pubitemid 43129523)
21. Stocco G, Cheok MH, Crews KR, et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther. 2009;85:164-172.
22. Hawwa AF, Millership JS, Collier PS, et al. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br J Clin Pharmacol. 2008;66:517-528.
23. von Ahsen N, Armstrong VW, Behrens C, et al. Association of inosine triphosphatase 94C.A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn's disease study. Clin Chem. 2005;51:2282-2288. (Pubitemid 41692571)
24. Gearry RB, Roberts RL, Barclay ML, et al. Lack of association between the ITPA 94C.A polymorphism and adverse effects from azathioprine. Pharmacogenetics. 2004;14:779-781. (Pubitemid 39552794)
25. Allorge D, Hamdan R, Broly F, et al. ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/ 6-mercaptopurine induced myelosuppression. Gut. 2005;54:565. (Pubitemid 40395509)
26. Breen DP, Marinaki AM, Arenas M, et al. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transpl. 2005;11:826-833. (Pubitemid 40975585)
27. Kurzawski M, Dziewanowski K, Lener A, et al. TPMT but not ITPA gene polymorphism influences the risk of azathioprine intolerance in renal transplant recipients. Eur J Clin Pharmacol. 2009;65:533-540.
28. Van Dieren JM, Hansen BE, Kuipers EJ, et al. Meta-analysis: inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2007;26:643-652. (Pubitemid 47246201)
29. De Ridder L, Van Dieren JM, Van Deventer HJ, et al. Pharmacogenetics of thiopurine therapy in paediatric IBD patients. Aliment Pharmacol Ther. 2006;23:1137-1141. (Pubitemid 43779353)
30. Palmieri O, Latiano A, Bossa F, et al. Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy. Aliment Pharmacol Ther. 2007;26:737-745. (Pubitemid 47246208)
31. Hoffmann JC, Preiss JC, Autschbach F, et al. Clinical practice guideline on diagnosis and treatment of Crohn's disease. Z Gastroenterol. 2008;46: 1094-1146.
32. Hoffmann JC, Zeitz M, Bischoff SC, et al. Diagnosis and therapy of ulcerative colitis: results of an evidence based consensus conference by the German society of Digestive and Metabolic Diseases and the competence network on inflammatory bowel disease. Z Gastroenterol. 2004;42:979-983.
33. Indjova D, Shipkova M, Atanasova S, et al. Determination of thiopurine methyltransferase phenotype in isolated human erythrocytes using a new simple nonradioactive HPLC method. Ther Drug Monit. 2003;25: 637-644. (Pubitemid 37238899)
34. Heller T, Oellerich M, Armstrong VW, et al. Rapid detection of ITPA 94C.A and IVS2 + 21A>C gene mutations by real-time fluorescence PCR and in vitro demonstration of effect of ITPA IVS2 + 21A>C polymorphism on splicing efficiency. Clin Chem. 2004;50: 2182-2184. (Pubitemid 39425868)
35. WHO. Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization Offset Publication No. 48; 1979.
36. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist. 2001;6: 162-176. (Pubitemid 32323455)
37. Bierau J, Lindhout M, Bakker JA. Pharmacogenetic significance of inosine triphosphatase. Pharmacogenetics 2007;8:121-1228.